November 2022 FDA Recall Drug by Imprimisrx Nj
D-0060-2023 - Subpotent Drug

This Class II drug recall was voluntarily initiated by Imprimisrx Nj on November 9, 2022 for the product Drug. The FDA reported the reason for recall as subpotent drug. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0060-2023

Reason for Recall
Subpotent Drug: The batches contain less than 90% of the labeled amount of latanoprost.
Initiated
11-09-2022
Reported
11-23-2022
Quantity
960 bottles

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
91140
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
ImprimisRx NJ
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Nationwide in the USA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
08-23-2023
Product Description About Product Description
Full technical description of the product.
Timolol-Latanoprost (0.5/0.005%) ophthalmic drops, Compounded, 5 mL bottle, Imprimis Rx, Ledgewood, NJ.

Batch or Lot Expiration Information

Lot# 06272022@3, Exp. date 11/24/2022
Lot# 08302022@1, Exp. date 01/27/2023